Esokem-L Capsule SR is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and accelerating gastric emptying, making it effective in treating functional dyspepsia, gastroesophageal reflux disease (GERD), and diabetic gastroparesis. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells, thereby providing symptomatic relief and promoting mucosal healing in acid-related conditions such as GERD, erosive esophagitis, and peptic ulcer disease. The sustained-release (SR) formulation of Esokem-L ensures prolonged therapeutic plasma concentrations, improving patient compliance and efficacy. This combination therapy addresses both motility dysfunction and acid hypersecretion, offering a comprehensive approach to upper gastrointestinal tract disorders. Esokem-L Capsule SR should be administered as prescribed by a healthcare professional, with consideration of contraindications such as hypersensitivity to either component, and caution in patients with renal or hepatic impairment. Common adverse effects may include headache, dizziness, and gastrointestinal disturbances. Regular monitoring is advised to optimize treatment outcomes and minimize potential side effects.